Circulating angiogenic factors and the risk of preeclampsia.
暂无分享,去创建一个
K. Lim | B. Sibai | E. Schisterman | V. Sukhatme | F. Epstein | R. Levine | Cong Qian | Kai-fun Yu | S. Maynard | B. Sachs | R. Thadhani | S. Karumanchi | Lucinda J England | Richard J. Levine | Ananth Karumanchiyx | Ananth Karumanchiyx | Ananth Karumanchiyx
[1] M. Paech,et al. Postcesarean Analgesia with Spinal Morphine, Clonidine, or Their Combination , 2004, Anesthesia and analgesia.
[2] Robert N. Taylor,et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. , 2004, The Journal of clinical endocrinology and metabolism.
[3] J. Foidart,et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. , 2003, The Journal of clinical endocrinology and metabolism.
[4] I. Ingemarsson,et al. Glomerular endotheliosis in normal pregnancy and pre‐eclampsia , 2003, BJOG : an international journal of obstetrics and gynaecology.
[5] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[6] D. Saller,et al. Second‐Trimester Maternal Serum Placental Growth Factor and Vascular Endothelial Growth Factor for Predicting Severe, Early‐Onset Preeclampsia , 2003, Obstetrics and gynecology.
[7] Y. Taketani,et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. , 2003, The Journal of clinical endocrinology and metabolism.
[8] D. Mukherjea,et al. Expression and Function of Placenta Growth Factor: Implications for Abnormal Placentation , 2003, The Journal of the Society for Gynecologic Investigation: JSGI.
[9] T. Libermann,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .
[10] J. Haigh,et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.
[11] Robert N. Taylor,et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. , 2003, American journal of obstetrics and gynecology.
[12] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. Alitalo,et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. , 2002, The American journal of pathology.
[14] C. Oudejans,et al. Plasma Placenta Growth Factor Levels in Midtrimester Pregnancies , 2001, Obstetrics and gynecology.
[15] S. Chow,et al. Decreased Maternal Serum Placenta Growth Factor in Early Second Trimester and Preeclampsia , 2001, Obstetrics and gynecology.
[16] H. Ho,et al. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. , 2001, American journal of obstetrics and gynecology.
[17] Jm Roberts,et al. Pathogenesis and genetics of pre-eclampsia , 2001, The Lancet.
[18] James J. Walker,et al. Pre-eclampsia , 2000, The Lancet.
[19] S. Gardiner,et al. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia , 2000, Nature.
[20] T. H. Wang,et al. Preeclampsia is associated with reduced serum levels of placenta growth factor. , 1998, American journal of obstetrics and gynecology.
[21] F. Ghezzi,et al. Disturbed Feto‐Maternal Cell Traffic in Preeclampsia , 1998, Obstetrics and gynecology.
[22] J. Cutler,et al. Trial of calcium to prevent preeclampsia. , 1997, The New England journal of medicine.
[23] C. Damsky,et al. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? , 1997, The Journal of clinical investigation.
[24] L. Poston,et al. Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function , 1997, British journal of obstetrics and gynaecology.
[25] R. Dersimonian,et al. Trial of Calcium for Preeclampsia Prevention (CPEP): rationale, design, and methods. , 1996, Controlled clinical trials.
[26] W. Bowes,et al. Birth‐Weight‐for‐Gestational‐Age Patterns by Race, Sex, and Parity in the United States Population , 1995, Obstetrics and gynecology.